EU co-financed projects

PRACELO is implementing the project entitled “The production of adipose tissue-derived allogeneic mesenchymal stem cells as compliant with the requirements of Good Manufacturing Practice – an active substance for the investigational medicinal product for advanced-therapy veterinary use, intended for clinical trials in the treatment of degenerative changes of joints and dysplasia in dogs”, co-financed by European Union funds within the framework of the Smart Growth Operational Programme 2014-2020, Measure 1.1.1.

Co-financing agreement No.: POIR.01.01.01-00-0281/16-00

THE OBJECTIVE OF THE PROJECT is to market an advanced-therapy medicinal product for veterinary use classified as a somatic cell therapy product offered in the form of allogeneic (one donor – many recipients) adipose tissue-derived mesenchymal stem cells, intended for use in treating degenerative joint diseases in dogs.

THE RESULT OF THE PROJECT will be the creation of a certified facility for producing active pharmaceutical ingredients of advanced-therapy medicinal products for veterinary use based on allogeneic stem cells produced in accordance with the requirements of Good Manufacturing Practice. The cGMP-compliant facility will be used to produce the active pharmaceutical ingredient, which in tandem with state-of-the-art production equipment will enable the creation of an innovative, advanced-therapy medicinal product using a completely novel technology. The technology will provide the high level of quality and safety required for the production of the active pharmaceutical ingredients, the investigational medicinal products, and the finished medicinal products authorised for marketing.

Amount of project co-financing by the EU: PLN 2 712 457,74

Total cost of the project: PLN 4 520 762,90

PRACELO is implementing the project entitled “New-generation medicinal product for veterinary use, intended for the treatment of atopic dermatitis, wounds and damaged skin”, co-financed by European Union funds within the framework of the Smart Growth Operational Programme 2014-2020, Measure 1.3: R&D activity financed with capital funds participation, Sub-measure 1.3.1: Support for R&D projects at the ‘pre-seed’ stage by proof of concept funds – BRIdge Alfa.

Financial Assistance Agreement No.: 3/Leonarto Alfa/2017 of 13.12.2017

Amount of project co-financing by the EU: PLN 800 000,00

Total cost of the project: PLN 1 000 000,00

PRACELO is implementing a project entailing the marketing of a stem cell-based product for veterinary use, classified as a somatic cell therapy product offered in the form of allogeneic (one donor – many recipients) Adipose Derived Mesenchymal Stem Cells (AD-MSC) from healthy donors, intended for the treatment of degenerative joint diseases and dysplasia in dogs, co-financed by European Union funds within the framework of the Smart Growth Operational Programme 2014-2020, Measure 1.3: R&D activity financed with capital funds participation, Sub-measure 1.3.1: Support for R&D projects at the ‘pre-seed’ stage by proof of concept funds – BRIdge Alfa.

Under the Financial Assistance Agreement concluded in Warsaw on 17 November 2017

Amount of project co-financing by the EU: PLN 800 000,00

Total cost of the project: PLN 1 000 000,00